These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 16084150)

  • 1. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS).
    Teerlink JR; McMurray JJ; Bourge RC; Cleland JG; Cotter G; Jondeau G; Krum H; Metra M; O'Connor CM; Parker JD; Torre-Amione G; Van Veldhuisen DJ; Frey A; Rainisio M; Kobrin I;
    Am Heart J; 2005 Jul; 150(1):46-53. PubMed ID: 16084150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.
    McMurray JJ; Teerlink JR; Cotter G; Bourge RC; Cleland JG; Jondeau G; Krum H; Metra M; O'Connor CM; Parker JD; Torre-Amione G; van Veldhuisen DJ; Lewsey J; Frey A; Rainisio M; Kobrin I;
    JAMA; 2007 Nov; 298(17):2009-19. PubMed ID: 17986694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure.
    Schalcher C; Cotter G; Reisin L; Bertel O; Kobrin I; Guyene TT; Kiowski W
    Am Heart J; 2001 Aug; 142(2):340-9. PubMed ID: 11479476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4).
    O'Connor CM; Gattis WA; Adams KF; Shah MR; Frey A; Gheorghiade M;
    Am Heart J; 2003 Feb; 145(2 Suppl):S58-9. PubMed ID: 12594454
    [No Abstract]   [Full Text] [Related]  

  • 5. Usefulness of an elevated troponin-I in predicting clinical events in patients admitted with acute heart failure and acute coronary syndrome (from the RITZ-4 trial).
    Gattis WA; O'Connor CM; Hasselblad V; Adams KF; Kobrin I; Gheorghiade M
    Am J Cardiol; 2004 Jun; 93(11):1436-7, A10. PubMed ID: 15165935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tezosentan in the treatment of acute heart failure.
    Tovar JM; Gums JG
    Ann Pharmacother; 2003 Dec; 37(12):1877-83. PubMed ID: 14632537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tezosentan. Actelion/Genentech.
    Rossetti E; De Servi S
    Curr Opin Investig Drugs; 2003 Mar; 4(3):323-8. PubMed ID: 12735233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tezosentan in the management of decompensated heart failure.
    Cheng JW
    Cardiol Rev; 2005; 13(1):28-34. PubMed ID: 15596026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure.
    Cotter G; Kaluski E; Stangl K; Pacher R; Richter C; Milo-Cotter O; Perchenet L; Kobrin I; Kaplan S; Rainisio M; Frey A; Neuhart E; Vered Z; Dingemanse J; Torre-Amione G
    Eur J Heart Fail; 2004 Aug; 6(5):601-9. PubMed ID: 15302008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tezosentan, a combined parenteral endothelin receptor antagonist, produces pulmonary vasodilation in lambs with acute and chronic pulmonary hypertension.
    Fitzgerald RK; Oishi P; Ovadia B; Ross GA; Reinhartz O; Johengen MJ; Fineman JR
    Pediatr Crit Care Med; 2004 Nov; 5(6):571-7. PubMed ID: 15530195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of randomized clinical trials in acute heart failure syndromes.
    Teerlink JR
    Am J Cardiol; 2005 Sep; 96(6A):59G-67G. PubMed ID: 16181824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan study (RITZ-4).
    O'Connor CM; Gattis WA; Adams KF; Shah MR; Kobrin I; Frey A; Gheorghiade M
    Am Heart J; 2002 Oct; 144(4):583-8. PubMed ID: 12360152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of endothelin receptor antagonism on acute lung injury induced by chlorine gas.
    Wang J; Oldner A; Winskog C; Edston E; Walther SM
    Crit Care Med; 2006 Jun; 34(6):1731-7. PubMed ID: 16625121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The development of new medical treatments for acute decompensated heart failure.
    Teerlink JR
    Heart Fail Monit; 2002; 2(4):129-37. PubMed ID: 12634887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tezosentan and right ventricular failure in patients with pulmonary hypertension undergoing cardiac surgery: the TACTICS trial.
    Denault AY; Pearl RG; Michler RE; Rao V; Tsui SS; Seitelberger R; Cromie M; Lindberg E; D'Armini AM
    J Cardiothorac Vasc Anesth; 2013 Dec; 27(6):1212-7. PubMed ID: 23523254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early worsening heart failure in patients admitted for acute heart failure: time course, hemodynamic predictors, and outcome.
    Torre-Amione G; Milo-Cotter O; Kaluski E; Perchenet L; Kobrin I; Frey A; Rund MM; Weatherley BD; Cotter G
    J Card Fail; 2009 Oct; 15(8):639-44. PubMed ID: 19786251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4).
    O'Connor CM; Gattis WA; Adams KF; Hasselblad V; Chandler B; Frey A; Kobrin I; Rainisio M; Shah MR; Teerlink J; Gheorghiade M;
    J Am Coll Cardiol; 2003 May; 41(9):1452-7. PubMed ID: 12742280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study.
    Cotter G; Metra M; Davison BA; Senger S; Bourge RC; Cleland JG; Jondeau G; Krum H; O'Connor CM; Parker JD; Torre-Amione G; van Veldhuisen DJ; Milo O; Kobrin I; Rainisio M; McMurray JJ; Teerlink JR;
    Eur J Heart Fail; 2014 Dec; 16(12):1362-71. PubMed ID: 25371147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of the RELAXin in acute heart failure study.
    Ponikowski P; Metra M; Teerlink JR; Unemori E; Felker GM; Voors AA; Filippatos G; Greenberg B; Teichman SL; Severin T; Mueller-Velten G; Cotter G; Davison BA
    Am Heart J; 2012 Feb; 163(2):149-55.e1. PubMed ID: 22305830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology of new agents for acute heart failure syndromes.
    Gheorghiade M; Teerlink JR; Mebazaa A
    Am J Cardiol; 2005 Sep; 96(6A):68G-73G. PubMed ID: 16181825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.